Fladrafinil — Safety, Research, Risks & Legal Status

Not medical advice. Fladrafinil is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Fluminafinil, fladrafinil hydrochloride, bis-dipropylaminophenethyl disulfide
Category	Research Chemical
french_approval	Approved in France and some EU countries for wakefulness promotion
prodrug_status	Prodrug that converts to flmodafinil in the body
modafinil_analog	Structurally related to modafinil and adrafinil but distinct pharmacokinetics
US legal status	Not FDA-approved in the US. Sold as a research chemical online. Approved in France and some European countries as a wakefulness-promoting agent. Regulatory status in the US is undefined; not federally scheduled.

What is Fladrafinil?

Fladrafinil is a prodrug of flmodafinil and is structurally related to modafinil and adrafinil. It is designed to promote wakefulness and enhance alertness, with proposed mechanisms involving dopamine modulation and norepinephrine signaling.

How it works

Prodrug that converts to flmodafinil in the body; both are wakefulness-promoting agents that enhance dopamine and norepinephrine signaling. Mechanism in humans not fully characterized but believed similar to modafinil.

Background & history

Developed in France in the 1980s-1990s as an alternative to adrafinil and modafinil. Approved in France and some European countries. Emerged in Western research-chemical supply in 2000s as a modafinil alternative.

What the research says

Limited human studies from European sources report wakefulness promotion and improved cognitive performance similar to modafinil. Animal studies confirm dopamine and norepinephrine effects. Human evidence is sparse compared to modafinil.

Reported effects

Reported wakefulness promotion and fatigue reduction
Studied for enhanced vigilance and cognitive performance in small trials
Reported improvements in motivation and focus (anecdotal)
Animal studies suggest dopamine and norepinephrine modulation
Theoretical potential for improved productivity during sustained attention tasks

Dosing & administration (informational)

Harm-reduction information only: European clinical studies employed moderate doses for wakefulness; underground sources often recommend lower doses than modafinil.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Limited human safety data; fewer controlled trials than modafinil
Potential for stimulant-related side effects (anxiety, insomnia, headache, elevated heart rate)
Quality of research-chemical sources is variable and often unverified
Unknown long-term effects and withdrawal potential
Contamination risk in unregulated supply chains

Drug & supplement interactions

Stimulant medications and psychostimulants (additive cardiovascular effects)
Medications affecting dopamine (potential for dysregulation)
Antidepressants and other serotonergics (interaction profile unclear)

Who should avoid it

Concurrent stimulant use (excessive tachycardia and anxiety risk)
Evening use (insomnia very likely)
High-dose escalation (tolerance and unknown long-term effects)
Individuals with cardiovascular disease or hypertension (stimulant-related risks)

How it is commonly combined

Combining with other stimulants or wakefulness-promoting agents increases cardiovascular stress and side-effect burden substantially.

Legal & regulatory. Not FDA-approved in the US. Sold as a research chemical online. Approved in France and some European countries as a wakefulness-promoting agent. Regulatory status in the US is undefined; not federally scheduled.

Quality & harm reduction

S
e
e
k
t
h
i
r
d
-
p
a
r
t
y
C
o
A
v
e
r
i
f
y
i
n
g
p
u
r
i
t
y
a
n
d
i
d
e
n
t
i
t
y
;
f
l
a
d
r
a
f
i
n
i
l
s
o
u
r
c
e
s
a
r
e
u
n
c
o
m
m
o
n
.
P
r
e
f
e
r
s
u
p
p
l
i
e
r
s
w
i
t
h
d
o
c
u
m
e
n
t
e
d
s
y
n
t
h
e
s
i
s
a
n
d
c
o
n
s
i
s
t
e
n
t
a
n
a
l
y
t
i
c
a
l
t
e
s
t
i
n
g
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

How is fladrafinil related to modafinil?

Fladrafinil is a prodrug that converts to flmodafinil (another modafinil analog) in the body. Both are structurally related to modafinil but have different potency and duration profiles.

Is fladrafinil stronger than modafinil?

Direct comparisons are limited. Some users report fladrafinil as more potent, but clinical evidence supporting this is sparse.

Where is fladrafinil approved?

Fladrafinil is approved as a wakefulness-promoting agent in France and some European countries. It is not FDA-approved in the US.

What are the side effects of fladrafinil?

Similar to modafinil: anxiety, insomnia, headache, increased heart rate, and reduced appetite. Long-term effects are largely unknown.

References & further reading

F
r
e
n
c
h
c
l
i
n
i
c
a
l
t
r
i
a
l
s
(
f
l
a
d
r
a
f
i
n
i
l
w
a
k
e
f
u
l
n
e
s
s
s
t
u
d
i
e
s
)
;
m
o
d
a
f
i
n
i
l
-
a
n
a
l
o
g
c
o
m
p
a
r
i
s
o
n
s
;
d
o
p
a
m
i
n
e
a
n
d
n
o
r
e
p
i
n
e
p
h
r
i
n
e
p
h
a
r
m
a
c
o
l
o
g
y
;
a
n
i
m
a
l
v
i
g
i
l
a
n
c
e
r
e
s
e
a
r
c
h
.